In a clinical trial conducted by our group, the anti-RANKL drug denosumab successfully halted bone resorption in FD and prevented the proliferation of altered BMSCs, leading to the decreased cellularity and normalized differentiation of affected BMSCs. Here, TNFSF11 is linked to Fabry disease.